IQV Quantitative Stock Analysis

IQVIA HOLDINGS INC (IQV) receives a 66% rating from Validea's P/B Growth Investor model, based on the strategy of Partha Mohanram, which favors low book-to-market stocks with sustained growth characteristics. The analysis, which is based on underlying fundamentals and valuation, indicates the stock passes key tests related to book/market ratio, return on assets, and cash flow, but fails tests related to advertising, capital expenditures, and research & development relative to assets. Mohanram's strategy aims to identify growth stocks that outperform by separating winners from losers among low book-to-market stocks using financial statement analysis.

Analysis

IQVIA Holdings Inc. (IQV) has received a 66% rating from Validea's P/B Growth Investor model, a strategy developed by Partha Mohanram that targets low book-to-market stocks demonstrating characteristics of sustained future growth. This score, derived from the company's underlying fundamentals and valuation, suggests moderate alignment with the model's criteria, falling below the 80% threshold that typically indicates some interest and the 90% mark for strong interest. IQV, a large-cap growth stock in the Biotechnology & Drugs sector, successfully passed several key financial tests including book/market ratio, return on assets, cash flow from operations to assets, the relationship between cash flow from operations to assets versus return on assets, return on assets variance, and sales variance. However, the company failed criteria related to advertising to assets, capital expenditures to assets, and research and development to assets. These failures highlight potential underinvestment in areas often crucial for driving future growth, despite the model identifying positive aspects in its current financial health and market valuation.

Key Decisions for Investors

• Investors should note IQV's moderate 66% rating and investigate further the reasons for failing tests on advertising, capital expenditure, and R&D to assets, as these could impact long-term growth prospects despite passing core financial health metrics.
• While the Partha Mohanram model identifies some favorable growth characteristics, the sub-80% score suggests a need for caution and additional due diligence before considering a new or increased position based solely on this specific strategy.
• Consider IQV's performance against these failed metrics in the context of its specific business model within the Biotechnology & Drugs industry, as industry norms for these expenditure ratios can vary.